Compare CRSP & OLED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRSP | OLED |
|---|---|---|
| Founded | 2013 | 1985 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.7B |
| IPO Year | 2016 | 1996 |
| Metric | CRSP | OLED |
|---|---|---|
| Price | $53.57 | $96.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 2 |
| Target Price | $70.29 | ★ $125.00 |
| AVG Volume (30 Days) | ★ 1.6M | 804.1K |
| Earning Date | 05-11-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 2.23% |
| EPS Growth | N/A | ★ 9.25 |
| EPS | N/A | ★ 0.76 |
| Revenue | $289,590,000.00 | ★ $650,611,000.00 |
| Revenue This Year | $807.72 | $5.88 |
| Revenue Next Year | $172.52 | $10.36 |
| P/E Ratio | ★ N/A | $127.12 |
| Revenue Growth | ★ 9169.85 | 0.45 |
| 52 Week Low | $33.03 | $83.64 |
| 52 Week High | $78.48 | $163.20 |
| Indicator | CRSP | OLED |
|---|---|---|
| Relative Strength Index (RSI) | 52.63 | 50.07 |
| Support Level | $50.91 | $93.03 |
| Resistance Level | $60.45 | $99.85 |
| Average True Range (ATR) | 2.72 | 3.99 |
| MACD | -0.31 | -0.08 |
| Stochastic Oscillator | 42.74 | 69.52 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Universal Display Corp researches, develops, and manufactures organic light-emitting diode, or OLED, technologies for use in displays for mobile phones, tablets, televisions, wearables, personal computers, automotive interiors, and the solid-state lighting market. OLED technologies are an alternative to light-emitting diode, or LED, technologies, in the solid-state lighting market, and liquid crystal displays in the flat-panel-display market. The Company has one reportable business segment being OLED technologies and materials. The large majority of the firm's revenue is generated in South Korea, with the rest coming from Japan, China, the United States, and other countries across the world.